Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Go back to Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations| (NASDAQ: SYRE) | Delayed: 90.25 -2.43 (2.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.68 | 52 Week High | $ | |||
| Open | $92.82 | 52 Week Low | $ | |||
| Day High | $93.34 | P/E | N/A | |||
| Day Low | $89.85 | EPS | $ | |||
| Volume | 3,357,068 | |||||
